Holen Sie sich die Stockscreener-App
13.48
7.24%
0.91
Vorhandelsmarkt:
13.44
-0.04
-0.30%
Schlusskurs vom Vortag:
$12.57
Offen:
$12.74
24-Stunden-Volumen:
1.49M
Relative Volume:
1.20
Marktkapitalisierung:
$1.31B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-44.84M
KGV:
-28.68
EPS:
-0.47
Netto-Cashflow:
$-44.23M
1W Leistung:
+18.66%
1M Leistung:
+20.57%
6M Leistung:
+27.89%
1J Leistung:
+122.81%
1-Tages-Spanne:
$12.45
$13.50
1-Wochen-Bereich:
$11.00
$13.50
52-Wochen-Spanne:
$6.04
$18.51
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Firmenname
Ars Pharmaceuticals Inc
Sektor
Branche
Telefon
858-771-9307
Adresse
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Vergleichen Sie SPRY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
13.48 | 1.31B | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Bestätigt | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | Raymond James | Outperform |
| 2024-03-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Eingeleitet | William Blair | Outperform |
| 2022-12-13 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten
ARS Pharmaceuticals lays down 2025 objectives for epinephrine nasal spray - MSN
ARS Pharmaceuticals Launches neffyinSchools Program Providing Free Life-Saving Needle-Free Epinephrine For Emergency Use to Eligible K-12 Schools - The Manila Times
ARS Pharma Launches Free Neffy Nasal Spray Program for U.S. Schools to Combat Allergic Reactions - StockTitan
When (SPRY) Moves Investors should Listen - Stock Traders Daily
Analysts Set ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Target Price at $26.00 - MarketBeat
Raymond James Issues Positive Forecast for ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up on Analyst Upgrade - MarketBeat
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps. - MSN
ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Up 7.6% After Analyst Upgrade - MarketBeat
Exploring Three High Growth Tech Stocks In The United States - Simply Wall St
ARS Pharmaceuticals shares surge on strong Q4 revenue for allergy spray - Investing.com Canada
ARS Pharmaceuticals (NASDAQ:SPRY) Price Target Raised to $27.00 at Leerink Partners - MarketBeat
ARS Pharmaceuticals Announces Preliminary Fourth Quarter - GlobeNewswire
ARS Pharmaceuticals' Neffy Nasal Spray Hits $7.1M in Sales Since Launch, Targets 80% Insurance Coverage - StockTitan
Barclays PLC Buys 73,127 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
(SPRY) Pivots Trading Plans and Risk Controls - Stock Traders Daily
Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Sells 50,000 Shares of Stock - MarketBeat
Ars pharmaceuticals director Laura Shawver sells $555k in stock By Investing.com - Investing.com Australia
Ars pharmaceuticals director Laura Shawver sells $555k in stock - Investing.com India
ARS Pharmaceuticals files for approval of neffy in Canada, U.K. - Yahoo Finance
ARS Pharma seeks approval for epinephrine spray in Canada and UK - Yahoo Finance
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 2.8%Time to Sell? - MarketBeat
ARS Pharmaceuticals Files for Approval of neffy® in Canada and the United Kingdom on Behalf of Licensing Partner ALK-Abelló A/S - The Manila Times
ARS Pharmaceuticals Files for Approval of neffy® in Canada - GlobeNewswire
ARS Pharma Expands Neffy Nasal Spray to UK & Canada, Targets 98% of Global Epinephrine Market - StockTitan
Top US Growth Companies With Insider Ownership In January 2025 - Simply Wall St
Market Sentiment Around Loss-Making ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - Simply Wall St
Barclays PLC Raises Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Down 3.6%Time to Sell? - MarketBeat
Institutional owners may ignore ARS Pharmaceuticals, Inc.'s (NASDAQ:SPRY) recent US$67m market cap decline as longer-term profits stay in the green - Yahoo Finance
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Receives $24.00 Average Target Price from Brokerages - MarketBeat
State Street Corp Acquires 193,321 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
Ars Pharmaceuticals' chief medical officer sells $1.17 million in stock By Investing.com - Investing.com Australia
ARS Pharmaceuticals (NASDAQ:SPRY) Stock Price Down 4% on Insider Selling - MarketBeat
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal Spray) is available on Express Scripts Commercial National Formularies - The Manila Times
ARS Pharmaceuticals Announces neffy® (Epinephrine Nasal - GlobeNewswire
Ars Pharmaceuticals' chief medical officer sells $1.17 million in stock - Investing.com
Ars Pharmaceuticals CEO sells $1.17 million in stock By Investing.com - Investing.com Canada
Insider Selling: ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Insider Sells 100,000 Shares of Stock - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap UpStill a Buy? - MarketBeat
ARS Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire
ARS Pharmaceuticals to Present at J.P. Morgan's Prestigious Healthcare Conference - StockTitan
Franklin Resources Inc. Trims Holdings in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
Insider Sell Alert: Justin Chakma Sells 144,605 Shares of ARS Ph - GuruFocus.com
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) COO Brian Dorsey Sells 25,000 Shares - MarketBeat
Justin Chakma Sells 27,272 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock - MarketBeat
ARS Pharmaceuticals (NASDAQ:SPRY) Trading Down 5.5%What's Next? - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stock Position in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) - MarketBeat
Finanzdaten der Ars Pharmaceuticals Inc-Aktie (SPRY)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):